Canaccord analyst WilliamBill Maughn raised the firm’s price target on Y-mAbs Therapeutics to $26 from $22 and keeps a Buy rating on the shares. The firm said they updated their model for 4Q results, lower expenses in line with management guidance, and roll forward our valuation to YE24.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on YMAB:
- Y-Mabs Therapeutics Welcomes New Board Member, Dr. Tagliaferri
- Y-mAbs Therapeutics sees FY24 revenue $95M-$100M, consensus $96.27M
- Y-mAbs Therapeutics reports Q4 EPS (2c), consensus (20c)
- Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
- YMAB Earnings this Week: How Will it Perform?
